Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia
- PMID: 15943222
- DOI: 10.1007/BF02850184
Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia
Abstract
Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.
Similar articles
-
The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia.Eur J Neurol. 2014 Dec;21(12):1486-e98. doi: 10.1111/ene.12517. Epub 2014 Jul 24. Eur J Neurol. 2014. PMID: 25060697
-
Personalized botulinum toxin type A therapy for cervical dystonia based on kinematic guidance.J Neurol. 2018 Jun;265(6):1269-1278. doi: 10.1007/s00415-018-8819-6. Epub 2018 Mar 20. J Neurol. 2018. PMID: 29557988 Clinical Trial.
-
An analysis of the efficacy of botulinum neurotoxin type a in treating cervical dystonia.Technol Health Care. 2024;32(4):2421-2430. doi: 10.3233/THC-231182. Technol Health Care. 2024. PMID: 38073352
-
[Treatment of focal dystonia with botulinum toxin A].Wien Klin Wochenschr. 2001;113 Suppl 4:6-10. Wien Klin Wochenschr. 2001. PMID: 15506045 Review. German.
-
Botulinum toxin therapy for cervical dystonia.Neurotox Res. 2006 Apr;9(2-3):145-8. doi: 10.1007/BF03033933. Neurotox Res. 2006. PMID: 16785112 Review.
Cited by
-
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).BMC Neurol. 2011 Nov 4;11:140. doi: 10.1186/1471-2377-11-140. BMC Neurol. 2011. PMID: 22054223 Free PMC article.
-
Immunogenicity of botulinum toxins.J Neural Transm (Vienna). 2013 Feb;120(2):275-90. doi: 10.1007/s00702-012-0893-9. Epub 2012 Sep 25. J Neural Transm (Vienna). 2013. PMID: 23008029 Free PMC article. Review.
-
Long-time molecular dynamics simulations of botulinum biotoxin type-A at different pH values and temperatures.J Mol Model. 2007 May;13(5):559-72. doi: 10.1007/s00894-007-0178-7. Epub 2007 Feb 27. J Mol Model. 2007. PMID: 17333307
-
Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.Neurotox Res. 2007 Dec;12(4):275-90. doi: 10.1007/BF03033911. Neurotox Res. 2007. PMID: 18201955 Review.
-
Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior.Toxins (Basel). 2018 Sep 11;10(9):368. doi: 10.3390/toxins10090368. Toxins (Basel). 2018. PMID: 30208596 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical